Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment

Gene Therapy

Volumn 17, Issue 2, 2010, Pages 202-216

  Huszthy, P C ^a,b   Immervoll, H ^a,b   Wang, J ^a   Goplen, D ^a,b   Miletic, H ^a,b   Eide, G E ^a,b   Bjerkvig, R ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NorLux Neuro Oncology   (Luxembourg)

Author keywords

Apoptotic index; G207; Glioblastoma xenograft; Microvessel density; Oncolytic herpes viral vector; Proliferation index

Indexed keywords

CD68 ANTIGEN; HERPESVIRUS VECTOR; ONCOLYTIC HERPES VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MICROENVIRONMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; QUANTITATIVE STUDY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; GENETIC VECTORS; GLIOBLASTOMA; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; RATTUS;

EID: 76749119314     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.130     Document Type: Article

References (52)

1. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
2. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205.
3. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactiva-table latent infections of mice and for replication in mouse cells. Virology 1989; 173: 276-283.
4. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999; 73: 6319-6326.
5. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000; 74: 3832-3841.
6. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867-874.
7. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17: 199-207.
8. Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSV vectors for glioblastoma therapy. Exp Rev Neurother 2009; 9: 505-517.
9. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396-6401.
10. Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 2006; 12: 643-652.
11. Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombos-pondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007; 67: 440-444.
12. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 2006; 12: 6791-6799.
13. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL et al. Oncolytic HSV armed with platelet factor 4, an antiangio-genic agent, shows enhanced efficacy. Mol Ther 2006; 14: 789-797.
14. Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006; 98: 38-50.
15. Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 2006; 66: 637-646.
16. McKeever PE, Davenport RD, Shakui P. Patterns of antigenic expression of human glioma cells. Crit Rev Neurobiol 1991; 6: 119-147.
17. Paulus W, Huettner C, Tonn JC. Collagens, integrins and the mesenchymal drift in glioblastomas: a comparison of biopsy specimens, spheroid and early monolayer cultures. Int J Cancer 1994; 58: 841-846.
18. Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O. Growth of precultured human glioma specimens in nude rat brain. J Neurosurg 1999; 90: 125-132.
19. Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, Engebraaten O. Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol (Berl) 2003; 105: 49-57.
20. Bjerkvig R, Tonnesen A, Laerum OD, Backlund EO. Multi-cellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg 1990; 72: 463-475.
21. Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 2006; 103: 16466-16471.
22. Huszthy PC, Svendsen A, Wilson JM, Kotin RM, Lonning PE, Bjerkvig R et al. Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts. Hum Gene Ther 2005; 16: 381-392.
23. Thorsen F, Afione S, Huszthy PC, Tysnes BB, Svendsen A, Bjerkvig R et al. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. J Gene Med 2006; 8: 1131-1140.
24. Goplen D, Wang J, Enger PO, Tysnes BB, Terzis AJ, Laerum OD et al. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 2006; 66: 9895-9902.
25. Huszthy PC, Goplen D, Thorsen F, Immervoll H, Wang J, Gutermann A et al. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clin Cancer Res 2008; 14: 1571-1580.
26. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7: 308-316.
27. Huszthy PC, Giroglou T, Tsinkalovsky O, Euskirchen P, Skaftnesmo KO, Bjerkvig R et al. Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One 2009; 4: e6314.
28. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
29. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-322.
30. Plaat B, Kole A, Mastik M, Hoekstra H, Molenaar W, Vaalburg W. Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur J Nucl Med 1999; 26: 328-332.
31. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K et al. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 2008; 14: 2049-2055.
32. Neder L, Colli BO, Machado HR, Carlotti Jr CG, Santos AC, Chimelli L. MIB-1 labeling index in astrocytic tumors-a clinicopathologic study. Clin Neuropathol 2004; 23: 262-270.
33. Torp SH. Diagnostic and prognostic role of Ki67 immunostain-ing in human astrocytomas using four different antibodies. Clin Neuropathol 2002; 21: 252-257.
34. Ehmann GL, McLean TI, Bachenheimer SL. Herpes simplex virus type 1 infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells. Virology 2000; 267: 335-349.
35. Hobbs 2nd WE, DeLuca NA. Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J Virol 1999; 73: 8245-8255.
36. Song B, Yeh KC, Liu J, Knipe DM. Herpes simplex virus gene products required for viral inhibition of expression of G1-phase functions. Virology 2001; 290: 320-328.
37. Burger PC. Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment. Semin Oncol 1986; 13: 16-26.
38. Deckert M, Reifenberger G, Wechsler W. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 1989; 115: 179-188.
39. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992; 66: 373-385.
40. Koyama AH, Fukumori T, Fujita M, Irie H, Adachi A. Physiological significance of apoptosis in animal virus infection. Microbes Infect/Institut Pasteur 2000; 2: 1111-1117.
41. Nguyen ML, Blaho JA. Apoptosis during herpes simplex virus infection. Adv Vir Res 2007; 69: 67-97.
42. Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 2004; 29: 486-494.
43. Cai W, Schaffer PA. Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells. J Virol 1992; 66: 2904-2915.
44. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72: 3307-3320.
45. Cinatl Jr J, Michaelis M, Driever PH, Cinatl J, Hrabeta J, Suhan T et al. Multimutated herpes simplex virus g 207 is a potent inhibitor of angiogenesis. Neoplasia 2004; 6: 725-735.
46. Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 2008; 16: 1382-1391.
47. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangio-blastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997; 94: 8761-8766.
48. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 2007; 67: 9398-9406.
49. Bauer J, Sminia T, Wouterlood FG, Dijkstra CD. Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune ence-phalomyelitis. J Neurosci Res 1994; 38: 365-375.
50. Dijkstra CD, Dopp EA, Joling P, Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macro-phage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 1985; 54: 589-599.
51. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12873-12878. (Pubitemid 44298654)
52. Kuriyama N, Kuriyama H, Julin CM, Lamborn KR, Israel MA. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res 2001; 61: 1805-1809.